Skip to main content
SpringerLink
Log in

Aktuelle Therapien der Dermatomyositis und Polymyositis

Current treatments of dermatomyositis and polymyositis

  • Leitthema
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

Zusammenfassung

Idiopathische, inflammatorische Myositiden sind chronische Erkrankungen vor allem der Skelettmuskulatur mit einer hohen Morbidität und Mortalität. Viele Patienten zeigen auch unter Glukokortikoid-Therapie einen progredienten oder rezidivierenden Verlauf, der den Einsatz von Immunsuppressiva, Biologika oder anderen Therapieverfahren nötig macht. Gute randomisierte, kontrollierte Studien zur Behandlung der primären Myositiden fehlen bis heute. Somit ist das optimale therapeutische Regime nicht definiert. Der Artikel gibt einen Überblick über die aktuelle Datenlage der Studien zu klassischen und modernen Therapieverfahren in der Behandlung der primären Myositiden.

Abstract

Idiopathic inflammatory myositides are chronic diseases affecting predominantly the musculoskeletal system and involving high morbidity and mortality. Even when treated with glucocorticosteroids, patients often experience a progressive or relapsing course of the disease, requiring additional immunosuppressants, biologicals, or other therapeutic interventions. Randomized controlled trials on the treatment of primary myositides are still lacking, which means that the optimum therapeutic regimen has still not been defined. This article reviews the current position indicated by the data collected in standard and modern therapeutic options for the treatment of idiopathic inflammatory myositides.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Adams EM, Pucino F, Yarboro C et al. (1999) A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures. J Rheumatol 26: 352–360

    PubMed  CAS  Google Scholar 

  2. Alexanderson H, Lundberg IE (2005) The role of exercise in the rehabilitation of idiopathic inflammatory myopathies. Curr Opin Rheumatol 17: 164–171

    Article  PubMed  Google Scholar 

  3. Amato AA, Griggs RC (2003) Treatment of idiopathic inflammatory myopathies. Curr Opin Neurol 16: 569–575

    Article  PubMed  CAS  Google Scholar 

  4. Anandacoomarasamy A, Howe G, Manolios N (2005) Advanced refractory polymyositis responding to infliximab. Rheumatology (Oxford) 44: 562–563

    Google Scholar 

  5. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292: 344–347

    Article  PubMed  CAS  Google Scholar 

  6. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292: 403–407

    Article  PubMed  CAS  Google Scholar 

  7. Bunch TW, Worthington JW, Combs JJ et al. (1980) Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med 92: 365–369

    PubMed  CAS  Google Scholar 

  8. Bunch TW (1981) Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum 24: 45–48

    Article  PubMed  CAS  Google Scholar 

  9. Bronner IM, Meulen MF van der, Visser M de et al. (2006) Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis 65: 1456–1461

    Article  PubMed  CAS  Google Scholar 

  10. Cagnoli M, Marchesoni A, Tosi S (1991) Combined steroid, methotrexate and chlorambucil therapy for steroid-resistant dermatomyositis. Clin Exp Rheumatol 9: 658–659

    PubMed  CAS  Google Scholar 

  11. Callen JP, Wortmann RL (2006) Dermatomyositis. Clin Dermatol 24: 363–373

    Article  PubMed  Google Scholar 

  12. Cherin P, Pelletier S, Teixeira A et al. (2002) Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 46: 467–474

    Article  PubMed  CAS  Google Scholar 

  13. Cherin P, Piette JC, Wechsler B et al. (1994) Intravenous gamma globulin as first line therapy in polymyositis a dermatomyositis: an open study in 11 adult patients. J Rheumatol 21: 1092–1097

    PubMed  CAS  Google Scholar 

  14. Choy EH, Hoogendijk JE, Lecky B, Winer JB (2005) Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 20: CD003643

    Google Scholar 

  15. Chung L, Genovese MC, Fiorentino DF (2007) A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 143: 763–767

    Article  PubMed  CAS  Google Scholar 

  16. Cordeiro AC, Isenberg DAN (2006) Treatment of inflammatory myopathies. Postgrad Med J 82: 417–424

    Article  PubMed  CAS  Google Scholar 

  17. Dachverband Osteologie (Hrsg) (2006) Evidenz-basierten Konsensus-Leitlinie zur Osteoporose bei chronischer Einnahme von Glukokortikoiden http://www.lutherhaus.de/osteo/leitlinien-dvo/PDFs/DVO-Leitlinie%20Glukokortikoid-Osteoporose%20Version%2006–09–07%20.pdf (Stand 01.10.2007)

  18. Dalakas MS (2006) Therapeutic targets in patients with inflammatory myopathies: present approaches and a look to the future. Neuromuscul Disord 16: 223–236 [Epub Mar 15]

    Article  PubMed  Google Scholar 

  19. Dalakas MC, Illa I, Dambrosia JM et al. (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329: 1993–200

    Article  PubMed  CAS  Google Scholar 

  20. Dastmalchi M, Alexanderson H, Loell I et al. (2007) Effect of physical training on the proportion of slow-twitch type I muscle fibers, a novel nonimmune-mediated mechanism for muscle impairment in polymyositis or dermatomyositis. Arthritis Rheum 57: 1303–1310

    Article  PubMed  Google Scholar 

  21. Dold S, Justiniano ME, Marquez J, Espinoza LR (2007) Treatment of early and refractory dermatomyositis with infliximab: a report of two cases. Clin Rheumatol 26: 1186–1188

    Article  PubMed  Google Scholar 

  22. Efthimiou P (2006) Tumor necrosis factor-alpha in inflammatory myopathies: pathophysiology and therapeutic implications. Semin Arthritis Rheum 36: 168–172

    Article  PubMed  CAS  Google Scholar 

  23. Gelber AC, Nousari HC, Wigley FM (2000) Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol 27: 1542–1545

    PubMed  CAS  Google Scholar 

  24. Genth E (2005) Entzündliche Muskelkrankheiten. Polymyositis, Dermatomyositis und Einschlusskörpermyositis. Internist 46: 1218–1232

    Article  PubMed  CAS  Google Scholar 

  25. Hengstman GJ, Hoogen FH van den, Engelen BG van (2004) Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up. Eur Neurol 52: 61–63

    Article  PubMed  CAS  Google Scholar 

  26. Iannone F, Scioscia C, Falappone PC et al. (2006) Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 33: 1802–1804

    PubMed  CAS  Google Scholar 

  27. Joffe MM, Love LA, Leff RL et al. (1993) Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 94: 379–387

    Article  PubMed  CAS  Google Scholar 

  28. Kasteler JS, Callen JP (1997) Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. J Am Acad Dermatol 36: 67–71

    Article  PubMed  CAS  Google Scholar 

  29. Lambotte O, Kotb R, Maigne G et al. (2005) Efficacy of rituximab in refractory polymyositis. J Rheumatol 32: 1369–1370

    PubMed  Google Scholar 

  30. Lange U, Piegsa M, Muller-Ladner U, Strunk J (2006) Anti-Jo-1 antibody positive polymyositis – successful therapy with leflunomide. Autoimmunity 39: 261–264

    Article  PubMed  Google Scholar 

  31. Le Guern V, Guillevin L (2007) Therapeutic apheresis for myositises. Transfus Apher Sci 36: 169–172

    Article  Google Scholar 

  32. Levine TD (2005) Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52: 601–607

    Article  PubMed  CAS  Google Scholar 

  33. Majithia V, Harisdangkul V (2005) Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 44: 386–389

    Google Scholar 

  34. Mastaglia FL, Phillps BA (2002) Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum Dis Clin North Am 28: 723–741

    Article  PubMed  Google Scholar 

  35. Mastaglia FL, Garlepp MJ, Phillips BA, Zilko PJ (2003) Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve 27: 407–425

    Article  PubMed  Google Scholar 

  36. Miller FW, Leitman SF, Cronin ME et al. (1992) Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 326: 1380–1384

    Article  PubMed  CAS  Google Scholar 

  37. Miller T, Al-Lozi MT, Lopate G, Pestronk A (2002) Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 73: 420–428

    Article  PubMed  CAS  Google Scholar 

  38. Noss EH, Hausner-Sypek DL, Weinblatt ME (2006) Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 33: 1021–1026

    PubMed  Google Scholar 

  39. Oddis CV, Sciurba FC, Elmagd KA, Starzl TE (1999) Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 353: 1762–1763

    Article  PubMed  CAS  Google Scholar 

  40. Oddis CV, Rider LG, Reed AM et al. International Myositis Assessment and Clinical Studies Group (2005) International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 52: 2607–2615

    Article  PubMed  Google Scholar 

  41. Pisoni CN, Cuadrado MJ, Khamashta MA et al. (2007) Mycophenolate mofetil treatment in resistant myositis. Rheumatology (Oxford) 46: 516–518

    Google Scholar 

  42. Phillips BA, Zilko P, Garlepp MJ, Mastaglia FL (1998) Frequency of relapses in patients with polymyositis and dermatomyositis. Muscle Nerve 21: 1668–1672

    Article  PubMed  CAS  Google Scholar 

  43. Qushmaq KA, Chalmers A, Esdaile JM (2000) Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review. J Rheumatol 27: 2855–2859

    PubMed  CAS  Google Scholar 

  44. Rider LG, Giannini EH, Brunner HI et al. International Myositis Assessment and Clinical Studies Group (2004) International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 50: 2281–2290

    Article  PubMed  Google Scholar 

  45. Schneider C, Gold R, Schäfers M, Toyka KV (2002) Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome. Muscle Nerve 25: 286–288

    Article  PubMed  CAS  Google Scholar 

  46. Schneider-Gold C, Hartung HP, Gold R (2006) Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases. Muscle Nerve 34: 284–291

    Article  PubMed  CAS  Google Scholar 

  47. Spiera R, Kagen L (1998) Extramuscular manifestations in idiopathic inflammatory myopathies. Curr Opin Rheumatol 10: 556–561

    Article  PubMed  CAS  Google Scholar 

  48. Villalba L, Hicks JE, Adams EM et al. (1998) Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 41: 392–399

    Article  PubMed  CAS  Google Scholar 

  49. Villalba L, Adams EM (1996) Update on therapy for refractory dermatomyositis and polymyositis. Curr Opin Rheumatol 8: 544–551

    Article  PubMed  CAS  Google Scholar 

  50. Vencovsky J, Jarosova K, Machacek S et al. (2000) Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 29: 95–102

    Article  PubMed  CAS  Google Scholar 

  51. Wilkes MR, Sereika SM, Fertig N et al. (2005) Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 52: 2439–2446

    Article  PubMed  CAS  Google Scholar 

  52. Woo TY, Callen JP, Voorhees JJ et al. (1984) Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol 10: 592–600

    Article  PubMed  CAS  Google Scholar 

  53. Yamasaki Y, Yamada H, Yamasaki M et al. (2007) Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 46: 124–130

    Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Klinik für Endokrinologie, Diabetologie und Rheumatologie, Universitätsklinikum Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Deutschland

    J. Richter & C. Iking-Konert

Authors
  1. J. Richter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Iking-Konert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Richter.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Richter, J., Iking-Konert, C. Aktuelle Therapien der Dermatomyositis und Polymyositis. Z. Rheumatol. 66, 686–692 (2007). https://doi.org/10.1007/s00393-007-0226-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-007-0226-9

Schlüsselwörter

Keywords

Search

Navigation